Tietze Lutz F, Schuster Heiko J, Hampel Sonja M, Rühl Stephan, Pfoh Roland
Institut für Organische und Biomolekulare Chemie der Georg-August-Universität Göttingen, Tammannstrasse 2, 37077 Göttingen, Germany.
Chemistry. 2008;14(3):895-901. doi: 10.1002/chem.200700988.
For the enantio- und diastereoselective synthesis of the prodrug 2, the N-tert-butyloxycarbonyl-protected amine 7 was alkylated with the enantiopure epoxide 14 to give the amide 10. A regio- and facial-selective metal-mediated cyclisation by using a cuprate led to 17 with an inversion of configuration at C10. Subsequent transformation of the hydroxy group in 17 by using the Appel procedure afforded (1S,10R)-9 with an unusual double inversion owing to neighbouring-group participation of the N-tert-butoxycarbonyl group. (1S,10R)-9 is the key intermediate in the synthesis of the prodrug 2, which has been developed for a selective treatment of cancer based on the antibody-directed enzyme prodrug therapy as an analogue of the natural antibiotic duocarmycine SA (1).
为了对前药2进行对映体和非对映体选择性合成,将N-叔丁氧羰基保护的胺7与对映体纯的环氧化物14进行烷基化反应,得到酰胺10。通过使用铜酸盐进行区域和立体选择性金属介导的环化反应,得到在C10处构型翻转的17。随后使用阿佩尔方法对17中的羟基进行转化,由于N-叔丁氧羰基的邻基参与,得到了具有不寻常的双重构型翻转的(1S,10R)-9。(1S,10R)-9是前药2合成中的关键中间体,前药2是基于抗体导向酶前药疗法开发的一种用于癌症选择性治疗的药物,它是天然抗生素双吲哚霉素SA(1)的类似物。